Key statistics dashboard for Nuvalent, Inc. (NUVL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Stock Data
| Price | $123.96 |
| Market Cap | $9.1B |
| Enterprise Value | $8.98B |
| Beta | 1.31 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -20.46 |
| Price / Book | 8.30 |
| P/S | 0.00 |
| EV/EBITDA | -26.84 |
| EV/Sales | 0.00 |
| EV/FCF | -28.69 |
| P/FCF | -29.21 |
| Earnings Yield | -4.62% |
| FCF Yield | -3.42% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -42.78% |
| Return on Assets | -33.81% |
| Return on Invested Capital | -35.11% |
| Return on Capital Employed | -35.11% |
Financial Health
| Current Ratio | 16.14 |
| Quick Ratio | 16.14 |
| Cash Ratio | 1.97 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.48 |
| Interest Coverage | -34.11 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 14.93 |
| Cash per share | 16.37 |
| FCF per share | -3.98 |
| Tangible Book Value per share | 14.93 |
| Dividend per share | 0.00 |
Related companies: ABVX · ARWR · AXSM · CRSP · CYTK · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of NUVL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks